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CASE PRESENTATION
A 60-year-old white Latino female with a clinical diagnosis
of diabetes mellitus (diagnosed in 1993) and hypertension
was referred to the chronic kidney disease clinic at
Brigham and Women’s Hospital for the evaluation of acute
kidney injury; serum creatinine had increased from a
baseline of 0.9 to 1.5 mg/dl in a 11-week period. She was
asymptomatic at the time of presentation. Her past
medical history included a total abdominal hysterectomy
with bilateral salpingo oophorectomy and upper
vaginectomy for high-grade squamous intraepithelial
lesion of the cervix, 11 weeks prior to presentation. Three
weeks prior to presentation (8 weeks after surgery) and
within a week of each other, she was evaluated for two
consecutive episodes of acute onset of chest pain with
pulmonary edema in the setting of severe hypertension.
Both episodes had blood pressures in excess of
190–200 mm Hg systolic that resolved with intravenous
diuretics. Cardiovascular workup revealed no evidence of
ischemic heart disease. Additionally, renal evaluation
included magnetic resonance angiography with and
without gadolinium, which did not reveal renal artery
stenosis. However, serum creatinine peaked at 1.9 mg/dl
immediately after surgical procedure and remained
elevated at 1.5 mg/dl throughout the course of her current
presentation (corresponding to a glomerular filtration rate
of 33 ml/min per 1.73m2, estimated by the modification in
diet in renal disease III (MDRD 3) equation). At
presentation, medications included amlodipine,
furosemide, metoprolol, lisinopril, atorvastatin, insulin
glargine, cyanocobalamin, acetylsalicylic acid, and
naproxen. The patient had no prior exposure to
radiocontrast agents. Physical examination revealed an
overweight women weighing 207 lbs with a blood
pressure of 142/60 mm Hg and a heart rate of 60 beats per
minute. The rest of the examination was unremarkable.
Her laboratory data is summarized in Table 1.
A postoperative kidney ultrasound showed no
hydronephrosis.
The etiology of the acute kidney injury was unclear.
Progressive diabetic nephropathy exacerbated by other
contributory factors, such as exposure to lisinopril,
acetylsalicylic acid, or naproxen, was regarded as the most
plausible explanation. Despite discontinuation of these
medications, kidney function did not improve; it worsened
in a 4-week period after presentation. Hence, a kidney
biopsy was performed.
KIDNEY BIOPSY
A total of nine glomeruli were in the core. The predominant
feature observed on light microscopy was a multifocal
deposition of calcium phosphate within the tubules
(basophilic, rounded concretions), in the interstitium, and
focally along tubular basement membranes (Figure 1a). The
deposits of calcium were non-birefringent under polarized
light and were best visualized in the sections stained with
von Kossa stain (Figure 1b). Degenerative changes of the
tubular epithelium were focally noted with flattening of
the epithelium. Tubular necrosis was not seen. An associated
focally dense lymphocyte-rich mixed inflammatory infiltrate
in the interstitium was also noted without interstitial
edema. Tubulitis was not present. Moderate tubular atrophy
and interstitial fibrosis affecting 30% of the parenchyma
were also observed. All of the glomeruli present in the
sample were hypertrophic and showed marked mesangial
sclerosis with the formation of distinctive acellular nodules
(Figure 1c). Globally sclerotic glomeruli were not observed.
On Periodic acid-Schiff and Jones’ methenamine silver stains,
the peripheral capillary loops showed thickened walls and
frequent double contours. Rare craters were also seen. There
was mild arteriosclerosis. Arterioles exhibited moderate
sclerosis of the vessel walls with accumulation of hyaline
material. On immunofluorescence microscopy, no significant
immune deposits were observed in the glomeruli. Electron
microscopy examination yielded no additional diagnostic
information, but confirmed the tubular degenerative changes
observed on light microscopy.
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CLINICAL DIAGNOSIS
Acute kidney injury from acute phosphate nephropathy and
diabetic nodular glomerulosclerosis.
CLINICAL FOLLOW-UP
On subsequent visits, a more detailed evaluation of the patient’s
history revealed exposure to oral sodium phospho-soda
(OSPS), also known as Fleet Phospho-soda (C.B. Fleet,
Lynchburg, VA, USA), 1 day before gynecological surgery
(11 weeks prior to presentation). Blood pressure was last
noted as 127/50 mm Hg. Kidney function has not returned to
baseline (serum creatinine of 1.9 mg per 100 ml with an
estimated glomerular filtration rate of 30 ml/min per 1.73m2
by MDRD 3 equation) 5 months after sodium phospho-soda
exposure. The most recent albumin-to-creatinine ratio is
513 mg albumin per gram of creatinine. Laboratory data of
the patient at the baseline and after OSPS exposure are
summarized in Figure 2.
DISCUSSION
Acute phosphate nephropathy is an unusual cause of acute
kidney injury. It is most frequently reported in elderly
patients, particularly among women, following exposure to
the bowel-cleansing preparation, OSPS. Acute phosphate
nephropathy is a diagnosis that tends to be overlooked, as
OSPS is not widely recognized as a precipitating cause of
acute kidney injury. We present a patient with an underlying
history of diabetes and hypertension with acute kidney injury
that was initially attributed to the progression of diabetic
nephropathy, but on kidney biopsy was diagnosed as acute
phosphate nephropathy secondary to OSPS exposure.
OSPS preparations are used as part of a bowel-cleansing
regimen; they prepare the colon for X-ray or endoscopic
examination as well as for surgery.1–4 OSPS preparations
emerged in 1990 as better alternatives to standard bowel
preparations and were regarded as very safe and effective
solutions for adequate mucosal visualization.1 However, as
their use continued to grow, case reports of serious electrolyte
disturbances (including some fatal outcomes) appeared in
Table 1 | Laboratory parameters at presentation
Investigation Value Reference value
Complete blood count
White blood cells 4.27 k/ml 4–10 k/ml
Hemoglobin 9.6 g/dl 11.5–16.4 g/dl
Platelets 260 k/ml 150–450 k/ml
Serum chemistry
Sodium 139 mmol/l 136–142 mmol/l
Potassium 4.5 mmol/l 3.5–5 mmol/l
Chloride 103 mmol/l 98–108 mmol/l
Calcium 9.1 mg/dl 8.8–10.5 mg/dl
Phosphate 3.8 mg/dl 2.4–5.0 mg/dl
Creatinine 1.5 mg/dl 0.7–1.3 mg/dl
Total CO2 27 mmol/l 23–32 mmol/l
Other chemistry
PTH 108.1 pg/ml 11–80 pg/ml
Glucose 178 mg/dl 54–118 mg/dl
Urinalysis
pH 6 4.5–8.0
Specific gravity 1.011 1.003–1.035
Blood 1+ 0
Protein 2+ 0
Serum electrophoresis No abnormal
electrophoretic
pattern noted
a b
c
Figure 1 | Renal biopsy findings in acute phospho-nephropathy. (a) Coarse basophilic, rounded deposits of calcium phosphate are
present within the lumina of tubules (hematoxylin–eosin, high-power field, original magnification  40). (b) The widespread multifocal
nature of the intratubular calcium–phosphate deposits is best illustrated with the von Kossa stain (von Kossa stain, high-power field, original
magnification  60). (c) Glomeruli displaying mesangial sclerosis with the formation of distinctive acellular nodules (periodic acid-Schiff
stain, high-power field, original magnification  40).
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the literature; they are associated with severe electrolyte
abnormalities (hyperphosphatemia, hypernatremia, hypoka-
lemia, hypocalcemia, and hypomagnesemia), metabolic
acidosis, acute kidney injury, and death when higher than
the recommended doses are used.5,6 The pathophysiology
and histologic lesion underlying acute kidney injury from
OSPS were unrecognized until the publication of a letter by
Desmeules et al.7 in the New England Journal of Medicine in
2003. The term acute phosphate nephropathy was used to
describe a syndrome observed in a 71-year-old woman whose
creatinine increased from 1.0 to 4.5 mg per 100 ml over a 10-
week period after administration of the recommended doses
of OSPS.7 Since then, there have been several cases in the
literature of biopsy-proven acute phosphate nephropathy
secondary to OSPS exposure.7–12
The potential for OSPS to cause acute kidney injury and
electrolyte disturbances led some authors to advise against
their use in patients with kidney, cardiac, or liver disease.11
The US Food and Drug Administration (FDA) in 2001, and
Health Canada in 2002, reviewed the safety of OSPS and
issued a report urging greater physician awareness.5,13
However, after the report by Desmeules et al., Markowitz
et al. performed a detailed study of 21 cases of acute kidney
injury after OSPS administration. Subsequently, in May 2006,
the FDA issued an alert noting the association between OSPS
preparations and acute phosphate nephropathy. The FDA
published a scientific background paper advising against the
use of these preparations in patients with kidney disease,
impaired renal function, dehydration, or uncorrected elec-
trolyte abnormalities.12 Multiple media reports have ap-
peared on the subject and the consumer advocacy group
Public Citizen has added OSPS preparations to its ‘worse
pills’ website.11 Recently, the American Society for Gastro-
intestinal Endoscopy (ASGE) and the Society of American
Gastrointestinal and Endoscopic Surgeons published an
addendum to their consensus statement warning on the
association of OSPS and phosphate nephropathy.1,14 How-
ever, these reports may have underestimated the actual
number of patients who develop acute phosphate nephro-
pathy since only the original cases of Desmules et al.7 and
Markowitz et al.9 have been published.
PREDISPOSING FACTORS FOR ACUTE PHOSPHATE
NEPHROPATHY
OSPS-induced acute kidney injury appears to be rare.
Predisposing conditions have not been elucidated in their
entirety. Contraindications to the use of OSPS include
electrolyte disorders, impaired kidney function, and renal
failure.12 Pathophysiologic factors thought to predispose
patients to acute phosphate nephropathy include inadequate
hydration, volume depletion and excessive OSPS dosing.12
Additionally, factors that are common in patients with acute
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Figure 2 | Acute phosphate nephropathy progression after OSPS exposure. Graph shows the trends of estimated glomerular filtration
rate, serum calcium and phosphate, and total urine protein-to-creatinine ratio at baseline and up to 5 months after exposure to OSPS.
The arrow marks the time when the patient was exposed to OSPS.
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phosphate nephropathy include female gender (this could
perhaps be related to the greater degree of volume depletion
caused by OSPS in the smaller body mass of elderly
women9,15,16), older age, history of hypertension, diabetes,
hyperparathyroidism and the use of angiotensin converting
enzyme inhibitors. Angiotensin receptor blockers, diuretics,
or non-steroidal anti-inflammatory drugs, exacerbate volume
depletion, particularly in older patients.9
CLINICAL PRESENTATION
There appears to be two distinct clinical patterns of acute
kidney injury after OSPS administration.8
Early-onset acute phosphate nephropathy
An acute pattern of presentation is present when acute kidney
injury is noted as part of a systemic syndrome after OSPS
exposure. These patients present with severe electrolytic
abnormalities (hypocalcemia and hyperphosphatemia) with
acute neurological symptoms, such as confusion, tetany and/
or lethargy, loss of consciousness, severe diarrhea, cardiac
arrest, or delay in awakening after anesthesia. Their
calcium–phosphate product usually increases to X100 mg/dl
but then returns to normal baseline values after exposure to
OSPS; conservative treatment, including phosphate-binding
resins and calcium gluconate, are recommended for the
hypercalcemia and hyperphosphatemia. Gonlusen et al.8
reviewed the presentation of 11 patients and observed a fatal
outcome in 27% of these individuals. Of those who survived,
renal function returned to baseline in 56% and/or improved
in 22% of the patients. The cause of acute kidney injury was
not definitively diagnosed, as kidney biopsies were not
performed consistently.8,11
Insidious onset acute phosphate nephropathy
In recent reports, an insidious form of OSPS-induced kidney
injury has been described. This syndrome is frequently
detected as an incidental finding (such as in the patient
reported herein) or presents with nonspecific symptoms
including malaise, nausea, or vomiting weeks to months after
OSPS exposure. Patients have normal electrolytes, a bland
urine sediment, and modest or minimal levels of proteinur-
ia.9 At follow-up, the majority of these patients develop
chronic kidney disease with a mean serum creatinine of
2.3 mg/dl.7,8,10,17 Some patients progress to end-stage renal
disease requiring hemodialysis.
PATHOGENESIS OF ACUTE PHOSPHATE NEPHROPATHY
The pathogenesis of acute kidney injury following OSPS
remains obscure, and is most likely multifactorial.11 Animal
studies (in rats), in which phosphate is infused via the
intraperitoneal route or feeding with a high-phosphorus diet,
demonstrate proximal tubular injury after 1 day, and
phosphate nephropathy in the kidney by the third day.18,19
Among humans, up to 20% of the phosphate in the OSPS is
reabsorbed,20 and a moderate increase in the dose of
phosphate absorption can cause severe hyperphosphatemia,
especially in patients with even a mild degree of existing renal
damage.16,21 Thus, it seems that in patients presenting
acutely, marked hyperphosphatemia may be directly tubulo-
toxic.8 Indeed, Gonlusen et al.8 have observed acute tubular
cell injury in tubules with calcium–phosphate deposition, but
have also reported the presence of tubular injury even
without concurrent calcium–phosphate deposition. Rapid
correction of hypocalcemia/hyperphosphatemia in patients of
this group may help prevent chronic injury and account for
the partial reversibility of renal function in most cases.
Although it is possible that the insidious form of acute
phosphate nephropathy has a different pathogenetic mechan-
ism, this has not been demonstrated definitively. It is likely
that in the patients who progress to chronic kidney disease
after exposure to OSPS, calcium–phosphate deposits causes
long-lasting tubular damage and subsequent fibrosis, and
nephron loss and fibrosis.11
MANAGEMENT OF ACUTE PHOSPHATE NEPHROPATHY
The management of acute phosphate nephropathy has two
important dimensions—acute management and prevention.
In those subjects who present with early-onset acute
phosphate nephropathy, the diagnosis is suggested if there
is a history of OSPS exposure, and associated laboratory
abnormalities are present. In these patients, treatment
targeted at the hyperphosphatemia and hypercalcemia are
key.16 In those who present with an insidious course and with
nonspecific symptoms, renal biopsy is important for
diagnosis because the phosphate and calcium levels are
usually normal at the time of presentation.
Preventing acute phosphate nephropathy is also very
important. The awareness of acute phosphate nephropathy
secondary to OSPS cannot be overemphasized. There exists
no clear cutoff glomerular filtration rate or serum creatinine
that contraindicates the administration of OSPS. Indeed,
both Markowitz et al. and Gonlusen et al. have observed
acute phosphate nephropathy in most subjects with normal
baseline creatinine values. It is thus imperative to avoid OSPS
in patients with predisposing risk factors—elderly age, co-
morbidities, such as diabetes mellitus and hypertension, and
patients on concomitant medications, such as angiotensin-
converting enzyme inhibitors, non-steroidal anti-inflamma-
tory drugs, and diuretics.
The patient we have presented here underscores the
importance of being alert to the syndrome of acute
phosphate nephropathy in patients with a normal serum
creatinine but with other risk factors. Although our patient
had a serum creatinine in the ‘normal range’ at 0.9 mg per
100 ml, she was in an older age group, had diabetes mellitus
and hypertension, and was being treated with an angiotensin-
converting enzyme inhibitors and non-steroidal anti-inflam-
matory drugs. The patient’s long-standing diabetes may
have increased her risk of developing an ileus in her
postoperative course. If a considerable amount of the OSPS
is absorbed in normal subjects,20 and a moderate increase in
phosphate absorption may be sufficient to cause severe
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hyperphosphatemia, it is reasonable to assume that a
prolonged intestinal transit period in our patient may have
predisposed her to acute phosphate nephropathy. Her kidney
biopsy also revealed arteriolar and arterial sclerosis, both
features known to pre-dispose to acute kidney injury after
OSPS administration.9 The other important point that our
patient illustrates is the value of performing a kidney biopsy in
patients with diabetic kidney disease who develop worsening
kidney function for no apparent reason. In view of her
nonspecific symptoms and normal laboratory parameters, it
was not possible to diagnose acute phosphate nephropathy on
clinical data alone; however, kidney biopsy made this diagnosis
possible. After this case came to our attention, the Brigham and
Women’s Hospital, at our request, implemented a warning in
its clinical information system so that each time OSPS is
prescribed in any of its pharmacological preparations, physi-
cians are required to weigh its risks and benefits (Figure 3).
We believe that these types of alerts are important in avoiding
this eminently preventable syndrome.
CONCLUSION
Both patients and health-care professionals should be vigilant of
acute kidney injury following the use of OSPS. Although this
agent is widely used as part of a colorectal-cleansing preparation
because of its efficacy, tolerability, and cost compared with
other available regimens, its use will most likely fall due to the
increased number of cases of acute phosphate nephropathy that
continue to be reported in the literature. Although acute
phosphate nephropathy has been recognized as a result of OSPS
use, it is a diagnosis that may be overlooked by nephrologists
and by other specialists. The adverse effects of phosphate-based
preparations may still be underestimated because there is no
clear serum creatinine or glomerular filtration rate cutoff that
permits their safe application.
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Renal failure from acute phosphate nephropathy is a rare but serious
Fleet Phospho-Soda Warning
adverse event associated with oral sodium phosphate bowel cleansing,
Fleet enemas and oral Fleet Phospho-Soda should be avoided in patients
with acute renal failure, chronic kidney disease, advanced age,
dehydration, and uncorrected electrolyte abnormalities.
Figure 3 | Fleet Phospho-soda warning in the hospital clinical
information system.
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